Cochrane · systematic review · CD013443
Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD)
Bertolini, F, Robertson, L, Bisson, JI, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
4
No studies
11
Included studies
NR
No studies 11 · 73.3%Ungraded 0 · 0%Very low 4 · 26.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Hydrocortisone compared to placebo for preventing post‐traumatic stress disorder (PTSD)
Population: adults (aged 18 and older) exposed to a traumatic event
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PTSD severity at 3 months ‐ not measured Hydrocortisone vs placebo | no estimate extracted | NR | No studies |
Dropout due to adverse events at 3 months ‐ not measured Hydrocortisone vs placebo | no estimate extracted | NR | No studies |
PTSD rate at 3 months ‐ not measured Hydrocortisone vs placebo | no estimate extracted | NR | No studies |
Functional disability at 3 months ‐ not measured Hydrocortisone vs placebo | no estimate extracted | NR | No studies |
Quality of life at 3 months ‐ not measured Hydrocortisone vs placebo | no estimate extracted | NR | No studies |
Propranolol compared to placebo for preventing post‐traumatic stress disorder (PTSD)
Population: adults (aged 18 and older) exposed to a traumatic event
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PTSD severity at 3 months Propranolol vs placebo | no estimate extracted | 3 studies · 86 participants | Very low Downgraded: risk of bias, imprecision |
Dropout due to adverse events at 3 months ‐ not measured Propranolol vs placebo | no estimate extracted | NR | No studies |
PTSD rate at 3 months Propranolol vs placebo | RR 0.77 [0.31, 1.92] | 3 studies · 88 participants | Very low Downgraded: risk of bias, imprecision |
Functional disability at 3 months ‐ not measured Propranolol vs placebo | no estimate extracted | NR | No studies |
Quality of life at 3 months ‐ not measured Propranolol vs placebo | no estimate extracted | NR | No studies |
Gabapentin compared to placebo for preventing post‐traumatic stress disorder (PTSD)
Population: adults (aged 18 and older) exposed to a traumatic event
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PTSD severity at 3 months Gabapentin vs placebo | no estimate extracted | 1 study · 1 participants | Very low Downgraded: risk of bias, imprecision |
Dropout due to adverse events at 3 months ‐ not measured Gabapentin vs placebo | no estimate extracted | NR | No studies |
PTSD rate at 3 months Gabapentin vs placebo | RR 0.8 [0.18, 3.59] | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision |
Functional disability at 3 months ‐ not measured Gabapentin vs placebo | no estimate extracted | NR | No studies |
Quality of life at 3 months ‐ not measured Gabapentin vs placebo | no estimate extracted | NR | No studies |